Products & Materials

New Products

See allHide authors and affiliations

Science  09 Dec 2016:
Vol. 354, Issue 6317, pp. 1309
DOI: 10.1126/science.354.6317.1309

ddPCR Multiplex Mutation Screening Kits

Droplet Digital PCR (ddPCR) Multiplex Mutation Screening Kits detect several key actionable cancer mutations and the wild-type allele in a single reaction. The combination of ddPCR and multiplexing technologies increases the throughput of genetic analysis to give clinical researchers more information per patient sample. Bio-Rad's ddPCR Multiplex Mutation Screening portfolio comprises KRAS G12/G13, KRAS Q61, NRAS G12, NRAS G12/G13, NRAS Q61, BRAF V600, and EGFR exon 19 deletion screening kits. This collection represents common actionable mutations found in numerous cancers and screened for during clinical research to connect specific genetic alterations with diagnosis, treatment efficacy, and disease recurrence. Sample partitioning in ddPCR enables detection of rare nucleic acid sequences in a complex background of competing sequences while minimizing the effect of inhibitory substances. The kits identify mutations present at allelic frequencies at or below 0.5%, making them ideal for use with FFPE and liquid biopsy samples.

Genome Fragment Analyzer

High-throughput genomic techniques require high-throughput instruments to measure the quality of input materials like DNA, genomic DNA (gDNA), and RNA. Advanced Analytical Technologies (AATI) designed the Fragment Analyzer INFINITY Capillary Electrophoresis System to meet this need in the workflow of automated laboratories. INFINITY is compatible with virtually any robotic arm, can run over 2,400 samples a day without intervention, and interfaces with laboratory information management systems to label samples automatically. It is also compatible with all of the original Fragment Analyzer qualitative and quantitative kits, which cover a wide range of nucleic acid sample types. To assess sample quality, AATI uses two kinds of metrics, or quality numbers: A fixed RNA quality number evaluates samples with consistent features like total RNA and correlates to the commonly used industry metric, while adaptive DNA and gDNA quality numbers have adjustable thresholds to appraise fragmented DNA and gDNA, which often vary widely between samples due to purification or shearing.

Profiling Panels

NanoString Technologies offers nCounter Vantage 3D Panels, a portfolio of products that power our 3D Biology products for simultaneous analysis of DNA, RNA, and proteins. Up to 800 targets can be detected and quantified from the same sample, which opens the opportunity for multianalyte signature discovery and validation on a single platform, even for challenging FFPE samples. nCounter Vantage 3D products can be mixed and matched to customize panels for specific applications and research questions. Comprehensive data collection and uniform data output from nCounter Analysis Systems, including the new SPRINT Profiler, can help scientists identify novel biomarkers for translational and diagnostics research.

Sequencing and Epigenetic Services

With its comprehensive repertoire of services, Zymo Research makes genome-wide epigenetic analysis available to every researcher. All next-generation epigenetic sequencing is competitively priced and features state-of-the-art sample prep technologies and workflows as well as cutting-edge bioinformatics. We offer the most comprehensive services for 16S ribosomal RNA and shotgun sequencing from any sample type. Using the most advanced pipelines for sample collection, nucleic acid isolation, and library preparation, ZymoBIOMICS allows for superior sequencing and analysis. The entire workflow is validated using the ZymoBIOMICS Microbial Community Standards, and provides non-biased community profile analysis. Tasks are customizable and can be combined to suit your needs, and include low-bioburden processing and accurate DNA/RNA isolation using the ZymoBIOMICS product line for the most accurate taxonomic profiling. Just send us your samples, and we will return the genome-wide analyses as customizable, publication-ready graphs and figures.

Transcriptome Profiling Assay

Molecular characterization of patient-derived xenografts used in cancer research provides valuable information on oncogenic mechanisms, candidate drug targets, and pathway status. Driver-Map offers a novel, comprehensive end-to-end service portfolio for identifying differential gene expression, mapping clinically actionable mutations in RNA, detecting cellular composition (immune/stromal components), and profiling immunotherapy targets. The Driver-Map transcriptome profiling assay has the unique advantage of selectively profiling human genes in a background of mouse cells, as well as providing pathway status. Researchers can profile and characterize with Driver-Map to determine if xenograft/patient-derived xenograft models have captured and retained the molecular and biological heterogeneity of the disease. Driver-Map offers superior sensitivity to detect low-to-medium abundant genes, and provides reproducible and reliable data even from low amounts (10 ng) of RNA. No cross-reactivity of real-time PCR primers with mouse transcripts occurs, making this assay highly specific to human cells.

  • Electronically submit your new product description or product literature information! Go to for more information.

  • Newly offered instrumentation, apparatus, and laboratory materials of interest to researchers in all disciplines in academic, industrial, and governmental organizations are featured in this space. Emphasis is given to purpose, chief characteristics, and availabilty of products and materials. Endorsement by Science or AAAS of any products or materials mentioned is not implied. Additional information may be obtained from the manufacturer or supplier.

Navigate This Article